Chemotherapy-Induced Neutropenia (CIN) Therapeutics -Pipeline Assessment and Market Forecasts to 2018
NEW YORK, Dec. 14, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
http://www.reportlinker.com/p0661217/Chemotherapy-Induced-Neutropenia-CIN-Therapeutics--Pipeline-Assessment-and-Market-Forecasts-to-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=General_Medicine_and_Specialty_Medicine
Chemotherapy-Induced Neutropenia (CIN) Therapeutics -Pipeline Assessment and Market Forecasts to 2018
Summary
GlobalData, the industry analysis specialist, has released its new report, "Chemotherapy-Induced Neutropenia (CIN) Therapeutics -Pipeline Assessment and Market Forecasts to 2018". The report is an essential source of information and analysis on the global CIN therapeutics market. The report identifies the key trends shaping and driving the global CIN therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global CIN sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
GlobalData estimates that the global Chemotherapy-induced Neutropenia (CIN) therapeutics market was valued at $3.6 billion in 2005 and grew at a Compound Annual Growth Rate (CAGR) of 5.8% to reach $4.8 billion in 2010. The market is forecast to grow at a CAGR of 2.3% over the next eight years to reach $5.8 billion by 2018. This decline in growth rate is primarily attributed to the expected patent expiry of Neupogen in 2013 (2006 in Europe) and Neulasta in 2015 which will make way for the entry of biosimilars (generic version of biologics) into the market. The increase in prescription population will help in partially offsetting the revenue loss due to the patent expiries.
Scope
The report provides information on the key drivers and challenges of the CIN market. Its scope includes -
- Analysis of seven key markets (the US, France, Germany, Italy, Spain, the UK and Japan), with CIN market revenues data from 2005 to 2010, and forecasts to 2018.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes such as long acting recombinant PEGylated G-CSFs, long-acting recombinant human albumin-G-CSFs, long acting glyco-PEGylated recombinant human G-CSFs, long-acting recombinant GM-CSFs, allogeneic cell-based therapies, recombinant fusion protein G-CSFs, neutrophil stimulators, recombinant protease inhibitors and hematopoeitic stem cell stimulators.
- Analysis of the current and future competition in the global CIN therapeutics market. Key market players covered are Eurofarma Laboratorios Ltda, Green Cross Corporation in collaboration with Symyoo, Intas Biopharmaceuticals Ltd. in collaboration with Apotex Inc. and Teva Pharmaceuticals.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the CIN therapeutics market.
- Analysis of key recent licensing and partnership agreements in CIN therapeutics market.
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global CIN market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global CIN therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What's the next big thing in the global CIN therapeutics market landscape? – Identify, understand and capitalize
1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 6
2 Chemotherapy-Induced Neutropenia (CIN) Therapeutics - Introduction 7
2.1 Overview 7
2.1.1 Classification of CIN 11
2.1.2 Febrile Neutropenia 12
2.2 Epidemiology 12
2.3 Symptoms 12
2.4 Etiology 13
2.5 Pathophysiology 13
2.6 Risk Factors for CIN 13
2.7 Diagnosis 17
2.8 Treatment of CIN 18
2.9 GlobalData Pipeline Report Guidance 24
3 Chemotherapy-Induced Neutropenia (CIN) Therapeutics - Market Characterization 25
3.1 CIN Therapeutics Market Size (2005-2010) - Global 25
3.2 CIN Therapeutics Market Forecast (2010-2018) - Global 27
3.3 CIN Therapeutics Market Size (2005-2010) - The US 29
3.4 CIN Therapeutics Market Forecast (2010-2018) - The US 31
3.5 CIN Therapeutics Market Size (2005-2010) - France 33
3.6 CIN Therapeutics Market Forecast (2010-2018) - France 35
3.7 CIN Therapeutics Market Size (2005-2010) - Germany 37
3.8 CIN Therapeutics Market Forecast (2010-2018) - Germany 39
3.9 CIN Therapeutics Market Size (2005-2010) - Italy 41
3.10 CIN Therapeutics Market Forecast (2010-2018) - Italy 43
3.11 CIN Therapeutics Market Size (2005-2010) - Spain 45
3.12 CIN Therapeutics Market Forecast (2010-2018) - Spain 47
3.13 CIN Therapeutics Market Size (2005-2010) - The UK 49
3.14 CIN Therapeutics Market Forecast (2010-2018) - The UK 51
3.15 CIN Therapeutics Market Size (2005-2010) - Japan 53
3.16 CIN Therapeutics Market Forecast (2010-2018) - Japan 54
3.17 Drivers and Barriers for the CIN Therapeutics Market 55
3.17.1 Drivers for the CIN Therapeutics Market 55
3.17.2 Barriers for the CIN Therapeutics Market 56
3.18 Key Events Impacting the Future Market 57
3.19 Opportunity and Unmet Need Analysis 58
3.19.1 Key Takeaway 59
4 Chemotherapy-Induced Neutropenia (CIN) Therapeutics - Competitive Assessment 60
4.1 Overview 60
4.2 Strategic Competitor Assessment 60
4.3 Product Profile for the Major Marketed Products in the CIN Therapeutics Market 62
4.3.1 Neulasta (pegfilgrastim) 62
4.3.2 Neupogen (filgrastim) 63
4.3.3 Leukine (sargramostim) 63
4.3.4 Granocyte/ Neutrogin (lenograstim) 64
4.4 Key Takeaway 66
5 Chemotherapy-Induced Neutropenia (CIN) Therapeutics - Pipeline Assessment 67
5.1 Overview 67
5.2 Strategic Pipeline Assessment 67
5.3 CIN Pipeline - Pipeline by Phases of Development 68
5.3.1 CIN Therapeutics - Pre-registration Pipeline 68
5.3.2 CIN Therapeutics - Phase III Pipeline 68
5.3.3 CIN Therapeutics - Phase II Pipeline 69
5.3.4 CIN Therapeutics - Phase I/II Pipeline 69
5.3.5 CIN Therapeutics - Phase I Pipeline 69
5.3.6 CIN Therapeutics - Preclinical Pipeline 69
5.4 CIN Therapeutics - Pipeline by Mechanism of Action 70
5.5 CIN Technology Trends Analytical Framework 71
5.6 Molecule Profile for Promising Drugs under Clinical Development 72
5.6.1 Neugranin 72
5.6.2 Lipegfilgrastim (XM22) 72
5.6.3 Filgrastim 73
5.6.4 Neukine 73
5.6.5 GCPGC 73
5.7 Key Takeaway 74
6 Chemotherapy-Induced Neutropenia (CIN) Therapeutics - Clinical Trials Mapping 75
6.1 Clinical Trials by Region/Country (the US, EU5 and Japan) 75
6.2 Clinical Trials by Phase 76
6.3 Clinical Trials by Status 77
6.4 Overall Sponsors 78
6.5 Prominent Sponsors 79
6.6 Participants in Therapeutic Clinical Trials - Companies 80
7 Chemotherapy-Induced Neutropenia (CIN) Therapeutics - Strategic Assessment 81
7.1 CIN Therapeutics: Implications for Future Market Competition 81
8 Chemotherapy-Induced Neutropenia (CIN) Therapeutics - Future Players 83
8.1 Introduction 83
8.2 Company Profiles 84
8.2.1 Teva Pharmaceutical Industries Limited 84
8.2.2 Eurofarma Laboratorios Ltda. 85
8.2.3 Green Cross Corporation 85
8.2.4 Intas Biopharmaceuticals Ltd. 86
8.2.5 Apotex Inc. 86
9 Chemotherapy-Induced Neutropenia (CIN) Therapeutics - Appendix 88
9.1 Definitions 88
9.2 Acronyms 88
9.3 Research Methodology 89
9.3.1 Coverage 89
9.3.2 Secondary Research 90
9.3.3 Forecasting 90
9.3.4 Primary Research 93
9.3.5 Expert Panel Validation 93
9.4 Contact Us 93
9.5 Disclaimer 93
9.6 Bibliography 94
List of Tables
Table 1: CIN Therapeutics Market, Global, Forecast, $m, 2005-2010 26
Table 2: CIN Therapeutics Market, Global, Forecast, $m, 2010-2018 28
Table 3: CIN Therapeutics Market, The US, Revenue, $m, 2005-2010 30
Table 4: CIN Therapeutics Market, The US, Forecast ($m), 2010-2018 32
Table 5: CIN Therapeutics Market, France, Revenue, $m, 2005-2010 34
Table 6: CIN Therapeutics Market, France, Forecast ($m), 2010-2018 36
Table 7: CIN Therapeutics Market, Germany, Revenue. $m, 2005-2010 38
Table 8: CIN Therapeutics Market, Germany, Forecast ($m), 2010-2018 40
Table 9: CIN Therapeutics Market, Italy, Revenue, $m, 2005-2010 42
Table 10: CIN Therapeutics Market, Italy, Forecast, $m, 2010-2018 44
Table 11: CIN Therapeutics Market, Spain, Revenue, $m, 2005-2010 46
Table 12: CIN Therapeutics Market, Spain, Forecast, $m, 2010-2018 48
Table 13: CIN Therapeutics Market, The UK, Revenue, $m, 2005-2010 50
Table 14: CIN Therapeutics Market, The UK, Forecast, $m, 2010-2018 52
Table 15: CIN Therapeutics Market, Japan, Revenue, $m, 2005-2010 53
Table 16: CIN Therapeutics Market, Japan, Forecast, $m, 2010-2018 54
Table 17: CIN Market, Global, Major Marketed Products Comparison, 2011 66
Table 18: CIN Therapeutics - Pre-registration Pipeline, 2011 68
Table 19: CIN Therapeutics - Phase III Pipeline, 2011 68
Table 20: CIN Therapeutics - Phase II Pipeline, 2011 69
Table 21: CIN Therapeutics - Phase I/II Pipeline, 2011 69
Table 22: CIN Therapeutics - Phase I Pipeline, 2011 69
Table 23: CIN Therapeutics - Preclinical Pipeline, 2011 69
Table 24: CIN Therapeutics - Clinical Trials by Country, 2011 75
Table 25: CIN Therapeutics - Clinical Trials by Phase, 2011 76
Table 26: CIN Therapeutics - Clinical Trials by Status (%), 2011 77
Table 27: CIN Therapeutics - Overall Sponsors (%), 2011 78
Table 28: CIN Therapeutics - Prominent Sponsors, 2011 79
Table 29: CIN Therapeutics - Top Companies Participating in Therapeutics Clinical Trials, 2011 80
Table 30: Teva Pharmaceuticals - Hematological Disorders Pipeline, 2011 84
Table 31: Teva Pharmaceuticals - CIN Pipeline, 2011 85
Table 32: Eurofarma Laboratorios Ltda., CIN Pipeline, 2011 85
Table 33: Green Cross Corporation, Hematological Disorders Pipeline, 2011 86
Table 34: Green Cross Corporation, CIN Pipeline, 2011 86
Table 35: Intas Biopharmaceuticals Ltd., CIN Pipeline, 2011 86
Table 36: Apotex Inc., CIN Pipeline, 2011 87
1.2 List of Figures
Figure 1: CIN Therapeutics, Hematopoesis - Formation and Development of Blood Cells 8
Figure 2: CIN Therapeutics, Risk of Neutropenic Complications in the First Cycle of Chemotherapy 9
Figure 3: CIN Therapeutics, The Course of Neutropenic Complications 10
Figure 4: CIN Therapeutics, CIN Grading by National Cancer Institute 11
Figure 5: CIN Therapeutics, Risk of Neutropenic Complications in the First Cycle of Chemotherapy by Tumor Type 14
Figure 6: CIN Therapeutics, Chemotherapy Regimens with a High (>20%) Febrile Neutropenia Risk 16
Figure 7: CIN Therapeutics, Bone Marrow Aspiration and Biopsy 17
Figure 8: CIN Therapeutics, Marketed Drugs 19
Figure 9: CIN Therapeutics, Risks and Benefits of CSF Use 20
Figure 10: CIN Therapeutics, Alignment of Recommendations for the Prophylactic Use of G-CSFs 21
Figure 11: CIN Therapeutics, NCCN - Decision Tree for Primary Prophylaxis 22
Figure 12: CIN Therapeutics, NCCN Guidelines for Treatment 23
Figure 13: CIN Therapeutics Market, Global, Revenue ($m), 2005-2010 25
Figure 14: CIN Therapeutics Market, Global, Forecast ($m), 2010-2018 27
Figure 15: CIN Therapeutics Market, the US, Revenue ($m), 2005-2010 29
Figure 16: CIN Therapeutics Market, The US, Forecast ($m), 2010-2018 31
Figure 17: CIN Therapeutics Market, France, Revenue ($m), 2005-2010 33
Figure 18: CIN Therapeutics Market, France, Forecast ($m), 2010-2018 35
Figure 19: CIN Therapeutics Market, Germany, Revenue ($m), 2005-2010 37
Figure 20: CIN Therapeutics Market, Germany, Forecast ($m), 2010-2018 39
Figure 21: CIN Therapeutics Market, Italy, Revenue ($m), 2005-2010 41
Figure 22: CIN Therapeutics Market, Italy, Forecast ($m), 2010-2018 43
Figure 23: CIN Therapeutics Market, Spain, Revenue ($m), 2005-2010 45
Figure 24: CIN Therapeutics Market, Spain, Forecast ($m), 2010-2018 47
Figure 25: CIN Therapeutics Market, The UK, Revenue ($m), 2005-2010 49
Figure 26: CIN Therapeutics Market, The UK, Forecast ($m), 2010-2018 51
Figure 27: CIN Therapeutics Market, Japan, Revenue ($m), 2005-2010 53
Figure 28: CIN Therapeutics Market, Japan, Forecast ($m), 2010-2018 54
Figure 29: CIN Therapeutics Market, Drivers and Restraints, 2011 57
Figure 30: CIN Therapeutics, Opportunity and Unmet Need, 2011 58
Figure 31: CIN Therapeutics - Strategic Competitor Assessment, 2011 61
Figure 32: CIN Therapeutics - Pipeline by Phase of Clinical Development, 2011 68
Figure 33: CIN Therapeutics - Clinical Pipeline by Mechanism of Action, 2011 70
Figure 34: CIN Therapeutics, Technology Trends Analytical Framework,, 2011 71
Figure 35: CIN Therapeutics, Technology Trends Analytical Framework, Description, 2011 72
Figure 36: CIN Therapeutics - Clinical Trials by Country, 2011 75
Figure 37: CIN Therapeutics - Clinical Trials by Phase (%), 2011 76
Figure 38: CIN Therapeutics - Clinical Trials by Status (%), 2011 77
Figure 39: CIN Therapeutics - Overall Sponsors (%), 2011 78
Figure 40: CIN Therapeutics - Prominent Sponsors (%), 2011 79
Figure 41: CIN Therapeutics Market, Implications for Future Market Competition, 2011 81
Figure 42: CIN Therapeutics - Pipeline by Company, 2011 83
Figure 43: GlobalData Market Forecasting Model 92
Companies mentioned
Teva Pharmaceutical Industries Limited
Eurofarma Laboratorios Ltda.
Green Cross Corporation
Intas Biopharmaceuticals Ltd.
Apotex Inc.
To order this report:
General Medicine and Specialty Medicine Industry: Chemotherapy-Induced Neutropenia (CIN) Therapeutics -Pipeline Assessment and Market Forecasts to 2018
Check our Industry Analysis and Insights
CONTACT
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article